Answers are grounded in this paper and cite their sources.
Background/Objectives: Bone fractures, particularly in older adults with osteoporosis, remain a major clinical challenge due to delayed union and nonunion despite advances in surgical techniques. This narrative review aimed to summarize the clinical evidence on unconcentrated bone marrow aspirate (BM) and bone marrow aspirate concentrate (BMAC) for promoting fracture healing and union. Methods: In this narrative review, clinical studies of BM or BMAC used as an adjunct to surgical treatment or as a percutaneous treatment for nonunion and delayed union were identified through a literature search and summarized descriptively. Outcomes included radiological union, clinical union, time to union, and reported complications. Results: In surgical settings (distraction osteogenesis, congenital pseudarthrosis, atypical femoral fractures, and atrophic mandibular fractures), one randomized trial and three non-randomized comparative studies, in all of which BMAC was part of a combined intervention, reported faster healing or a shorter time to union (three studies) and fewer complications or refractures (two studies). In 13 studies of percutaneous injection for nonunion, 11 of which used unconcentrated BM, reported union rates ranging from 50% to 94.4%, and the unweighted median of the study-level summary time to radiological union was 20.7 weeks. In two BMAC studies, union or callus formation was associated with the number or concentration of progenitor cells delivered. One uncontrolled series of infected tibial nonunion without bone defects reported union and resolution of infection after BMAC containing granulocyte precursors, without antibiotics. Conclusions: BM- and BMAC-based interventions have been associated with favorable outcomes in selected clinical settings. However, small samples, uncontrolled designs, heterogeneous products and populations, and concomitant treatments limit certainty about the independent contribution of BMAC and its safety relative to standard treatment. The available evidence is of low certainty. Further large-scale randomized controlled trials are warranted to establish standardized protocols, optimize preparation methods, and evaluate long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: